Introduction
Nicotinamide adenine dinucleotide (NAD + ) and its reduced form (NADH) play a central role in maintaining cellular metabolism and cell survival. NAD + serves as an electron acceptor and transfers energy between different metabolic pathways such as fatty acid oxidation (FAO) and the tricarboxylic acid cycle (TCA; also known as the Krebs cycle). NADH on the other hand is an electron donor that is oxidized during aerobic glycolysis and oxidative phosphorylation (OXPHOS), leading to ATP production (1, 2) . In addition, when released into the extracellular environment, NAD + can modulate various cell signalling pathways including immune and inflammatory responses (2) (3) (4) (5) (6) . The importance of NAD + metabolism in immunity was first highlighted among individuals who got cured of pellagra (a nutritional deficiency condition), upon supplementation of their diet with the NAD + precursor called niacin, now known as vitamin B 3 or nicotinic acid (NA). The role of NAD + during aging and during neurodegenerative diseases has been well described (2, 3) . Increasing evidence associates the availability of NAD + with perturbed immune responses during infections, suggesting the potential of targeting the cellular NAD + world (7) for the treatment of infectious diseases. Here, we review recent findings emphasizing the role of NAD + metabolism during infections, how enzymes of the NAD + network regulate glycolysis and how the cellular NAD + network could be modulated to boost host fitness and pathogen clearance, with specific emphasis on Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). We discuss the clinical relevance of this approach.
NAD + biosynthesis in eukaryotes
In eukaryotes, NAD + availability is determined by the rate of NAD + biosynthesis or degradation. There are several NAD + precursors. First, dietary tryptophan (TRP) can serve as an NAD + precursor through an eight-step de novo pathway [reviewed by Fang et al. (3) ], which includes the conversion of TRP to N-formylkynurenine by either indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO; Fig. 1 ). N-formylkynurenine is then converted to quinolinic acid (QA), which is then transformed to nicotinic acid mononucleotide (NAMN) by quinolinate phosphoribosyl transferase (QPRT). NAMN links the de novo pathway with the Priess-Handler pathway, which is a three-step pathway using dietary NA to generate NAMN. Nicotinic acid phosphoribosyl transferase (NAPRT) enzyme is required for the conversion of NA to NAMN. The enzymes nicotinamide mononucleotide adenylyltransferase (NMNAT) [1] [2] [3] NAD + serves as an electron acceptor for glycolysis, a process that metabolizes glucose or glycogen, and is reduced to NADH. However, NAD + must be regenerated from NADH for continued glycolytic flux, a process that happens within the mitochondria. This glycolytic flux leads to the production of pyruvate, which in the presence of oxygen, gets oxidized to produce 36 ATP molecules. In the absence of oxygen (hypoxia), pyruvate gets catalyzed to lactate, yielding two ATP molecules, a process also known as aerobic glycolysis or the Warburg effect. If NAD + is not regenerated, glycolysis (and other metabolic pathways) will stop, creating a disruption in mitochondrial metabolism and an imbalance in cellular redox homeostasis.
Degradation of NAD + to NAM in the salvage pathway ( Fig. 1) is the result of the activities of NAD + -consuming + biosynthetic pathways and the enzymes involved. In mammals NAD + levels are maintained by three major pathways. First is the de novo biosynthesis pathway that uses dietary TRP to generate NAD + through the kynurenine pathway. The conversion of TRP to N-formylkynurenine is catalyzed by the rate-limiting enzyme IDO. N-formylkynurenine is spontaneously converted to 2-amino-3-carboxymuconate semialdehyde (ACMS) in a total of three steps and finally to QA, which is then converted to NAMN by QPRT. ACMS can be decarboxylated into AMS by ACMS decarboxylase (ACMSD). AMS can be oxidized into acetyl CoA through the TCA cycle. NAMN helps in linking the de novo pathway to the Priess-Handler pathway, which generates NAMN from dietary NA using NAPRT. NAMN gets converted into NAAD by NAMN transferases (NMNAT 1-3 (13) . In activated monocytes and macrophages, the lipopolysaccharide (LPS)-mediated increase in TNFα can regulate the expression of NAMPT, a key enzyme controlling NAD + homeostasis (14) . Via p38/JNK kinases and NFκB/AP1 transcription factors, TNFα can result in the induction of CD38 which can further scavenge the cellular NAD + pool (15) . NAD + has been shown to inhibit T-cell proliferation and cytotoxic activity in vitro and in vivo (16) . When injected in mice, NAD + specifically induces apoptosis of both CD4 + and CD8 + T cells but not B cells (17) . Recently, Rodriguez Cetina Biefer et al. showed that NAD + can induce mast cell-mediated CD4 + T-cell differentiation, which was independent of MHCII and the T-cell receptor signalling machinery (18) . In these studies, NAD + -mediated regulation of the CD4 + T cell fate rendered mice resistant to lethal doses of Listeria monocytogenes.
Enzymes of the NAD + network, NAD + levels and immune fitness
In order to survive and persist, many pathogens hijack enzymes that modulate the host's NAD + homeostasis (19) (20) (21) (22) , thus influencing NAD + levels and leading to metabolic dysfunction. Fluctuations in NAD + levels have been reported in cells infected by different classes of intracellular pathogens. This modulation of NAD + levels is predicted to affect effector functions of immune cells and, consequently, affect the clearance or persistence of infections. NAD + levels are largely dependent on the TRP-catabolizing enzyme IDO and the NAD + -consuming enzymes SIRTs, PARPs and CD38 (cluster of differentiation 38). These enzymes play important roles in energy metabolism, cell survival, proliferation and effector functions, making them potential targets for designing hostdirected therapies (HDT).
Indoleamine 2,3-dioxygenase
IDO is the rate-limiting enzyme for the TRP catabolic pathway, is responsible for the de novo synthesis of NAD + and plays an important role in the metabolic state of cancer cells and cells infected with bacteria or viruses (23, 24) . IDO decreases glycolysis and glutaminolysis by activating the kinase GCN2 and increasing FAO by activating AhR (aryl hydrocarbon receptor) (25) . AhR and HIF-1α (hypoxia inducible factor 1α) together recognize metabolic changes in immune cells, such as T cells and macrophages (26) . Norisoboldine, a natural AhR agonist, promotes regulatory T-cell (T reg ) differentiation and attenuates colitis via targeting glycolysis and the NAD + -SIRT1 signalling pathway (27) .
IDO metabolites such as QA have demonstrated bactericidal activity against TRP-auxotrophic pathogens like Chlamydia psittaci, Leishmania donovani and Toxoplasma gondii (23) , indicating a possible IDO-mediated homeostatic control of innate and adaptive immunity. However, in infection by pathogens such as uropathogenic Escherichia coli and Mtb, which can synthesize their own TRP, IDO metabolites impair the function of antigen-specific CD4 + T-cell responses via the expansion of T regs and myeloid-derived suppressor cells (MDSCs), thus creating an immunosuppressive microenvironment (24, 28, 29) . It is noteworthy that this immunosuppressive environment within the TB granuloma could aid in Mtb persistence (29) .
Due to the fact that TRP catabolism promotes tumour growth, significant progress has been made to identify inhibitors of IDO and many of them are currently being evaluated in clinical trials viz. indoximod NLG8189 (#NCT02835729 and #NCT03301636 at https://clinicaltrials.gov/) and Epacadostat INCB024360 (#NCT02318277 and #NCT03322540). Recently, it was shown in a macaque model of TB that innate and adaptive immunity against Mtb could be enhanced by inhibiting IDO activity via D-1 methyl tryptophan (D-1MT) (29) . D-1MT also altered TB granuloma organization, with more T cells translocated to the lesion core.
Sirtuins
The seven-member mammalian SIRT family plays a crucial role in restoring homeostasis during stress responses. The deacetylase activity of SIRTs depends entirely on NAD + and is linked to DNA repair, apoptosis and healthy ageing, and is more recently being linked to inflammation. In particular, SIRT1 epigenetically reprograms inflammation by altering histones and transcription factors such as HIF-1α, NF-κB and API (30) , making SIRT1 activators/inhibitors attractive alternatives for modulating host immuno-metabolic circuits (31) (32) (33) (34) (35) .
SIRTs influence cells' metabolism and more specifically glycolysis either directly by deacetylating the lysine residues of glycolytic enzymes or indirectly by deacetylating the transcription factors regulating the gene expression of glycolytic enzymes. SIRT1 and SIRT2 both can affect glycolytic flux by deacetylating and inactivating HIF-1α (36, 37) , an important transcription factor that regulates the expression of genes such as Glut1, Hk2, Pkm and Ldha (38) . Additionally, SIRT1 deacetylates PGC-1α and together they control the expression of glycolytic and gluconeogenic genes (39) . SIRT3, a mitochondrial sirtuin, has been shown to inhibit the Warburg effect by deacetylating K321 of pyruvate dehydrogenase E1α1 (PDHA1), thus enhancing its activity (40) . SIRTs also epigenetically control glycolysis via deacetylation of histones. Reduced deacetylation of H4K16 by SIRT1 resulted in increased glycolysis in activated skeletal muscle cells (41) . The SIRT1-mediated reduction in HIF-1α expression could also be due to the deacetylation of H3K14 at the promoter of the Hif1A gene (42) . Similarly, SIRT6-mediated deacetylation of H3K9 could regulate glucose homeostasis (43) .
Because SIRT1 modulation could have beneficial effects on human diseases, there is a growing interest in the discovery of small molecules that modify SIRT activity (44, 45) . Resveratrol, a SIRT1-activating drug and a potent natural polyphenol, was found to improve the general health of mice fed with a high-calorie diet (46) . A nutraceutical formulation containing resveratrol (resVida) demonstrated beneficial effects in healthy obese men (47) , and SRT501, a commercial micronized resveratrol formulation, improved insulin sensitivity and lowered blood glucose in patients with type 2 diabetes in a Phase IIa trial (48) . SRT1720, another SIRT1-activating compound, induced apoptosis in multiple myeloma cells in vitro in a pre-clinical evaluation for cancer treatment (49) .
Although these SIRT modulators have possible therapeutic use in age-related diseases, cancer and inflammation, their use can be extended to treat bacterial and viral infections. It has been shown that resveratrol has anti-viral properties against a range of viruses including influenza and human immunodeficiency virus (HIV) (50), possibly by suppressing NF-κB activation in infected cells. Resveratrol can also induce apoptosis of activated T cells during severe inflammation (51) . We have recently shown that Mtb-infected monocytes have reduced levels of SIRT1, and activating SIRT1 by resveratrol and SRT1720 inhibits Mtb in vitro and, together with isoniazid (INH) monotherapy, reduced Mtb growth in infected mice (19) , indicating the potential of SIRT1 activators as adjunctive host-directed drugs for TB. This resveratrol-mediated efficacy against Mtb could be due the known effect of resveratrol on the Warburg effect (52), which is induced by Mtb in mouse lungs (53) . Silencing of SIRT1 also happens in the brain of simian immunodeficiency virus (SIV)-infected macaques (54) , indicating the importance of activating SIRT1 for correcting neuropathological perturbations in AIDS patients. Of note, the specificity of SIRT1 activators has always been questioned (55) .
Poly(ADP-ribose) polymerases
The other core regulatory enzyme family that needs NAD + for its activity is the PARP family. PARP1 is the most abundant and highly expressed nuclear enzyme and is widely involved in DNA damage responses, apoptosis and epigenetic modifications. These enzymes form polymers of ADP-ribose (PAR) from NAD + that can couple onto target proteins (56) . LPS induces PARP1 activity through the MAPK signalling, causing an increase in inflammatory mediators such as TNF-α and IFN-γ, and other chemotaxis molecules, mostly driven by NF-κB signalling (57) .
Overactivity of PARP1 caused by DNA strand-breaks or metabolic insults can lead to NAD + depletion and ultimately apoptosis. NAD + depletion due to hyperactivation of PARP1 also decreases activation of the NAD + -SIRT1-PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1) axis, thus triggering mitochondrial abnormalities (58) . In neurons and the glioblastoma-derived cell line LN428, however, PARP1 activation is not dependent on NAD + depletion, but results in PAR-dependent inhibition of glycolysis via inhibition of hexokinase 1, which precedes the NAD + depletion (59, 60) . This inhibition of glycolysis happens due to the PARylation of hexokinase, which is present on the outer mitochondrial membrane, leading to its release from the mitochondrial membrane (59) . PARP1 activation also regulates glycolysis and mitochondrial homeostasis by regulating the activity of HIF-2α (61) .
Some pathogens can take advantage of host cell signalling by activating PARP1. For instance, Trypanosoma cruzi induces the ROS-PARP1-RelA pathway involved in up-regulating cytokine production in cardiomyocytes, resulting in sustained inflammation (62) . Helicobacter pylori induces PAR production in gastric cells (63) and Salmonella enterica serovar Typhimurium enhances nuclear PARP1 in epithelial cells (64) , leading to chronic inflammation and disease. In contrast, Chlamydia trachomatis can degrade PARP1 to limit inflammatory responses (65) .
The role of PARP during Mtb infection remains unclear; however, Mycobacterium avium recombinant protein MAV2054 was shown to activate PARP (Fig. 2) (66) . Mtb is known to modulate pathways being regulated by PARP1. Mtb produces necrotizing toxin, a NAD + glycohydrolase that can deplete host NAD + levels and cause macrophage cell death (67) . A similar NAD + glycohydrolase is also released by Streptococcus pyogenes upon infection of host cells, resulting in hyperactivation of PARP1, and the release of the proinflammatory mediator high-mobility group box-1 (HMGB1) protein from the nucleus, by a PARP1-dependent mechanism (68) . HMGB1 has been shown to be released during experimental TB (69) and increased levels have been suggested to reflect the inflammatory status of monocytes in patients with active TB (70) .
PARP1 is regarded as an important molecular target in tumours, leading to the development of PARP1 inhibitors, many of which are in clinical trials (71) . Thus, one can envisage the repurposing of PARP1 inhibitors for infectious disease such as TB (Fig. 2) . Indeed olaparib, the leading PARP1 inhibitor for cancer treatment, can decrease numbers of T. cruzi amastigotes in cell culture (72) . Additionally, another PARP1 inhibitor, 3-aminobenzamide (3-AB), was protective against meningitis-associated central nervous system complications resulting from Streptococcus pneumoniae (73). 3-AB has also recently been shown to attenuate the progression of arthritis induced by an adjuvant (i.e. heat-killed Mtb) in a mouse model (74) . Future studies should decipher the effect of inhibiting PARP1 in interfering with Mtb infection in vivo.
Cluster of differentiation 38
Another important consumer of NAD + is CD38, an ectoenzyme that is widely expressed in immune cells and plays an important role in cell homeostasis and activation (75) . Also known as ADP-ribosyl cyclase, CD38 is a type II membraneanchored enzyme that generates cADPR and NAADP, two potent secondary messengers for Ca 2+ signalling, when the extracellular NAD + content is increased upon damage or infection (76) . First characterized as a lymphocyte surface antigen, CD38 is also broadly distributed throughout most tissues in the body, making it a main cellular NADase in mammalian tissues (77) .
CD38 expression increases during various infections, including Mtb (78), acting as an indicator of immune activation. Furthermore, overexpression of CD38 in human embryonic kidney 293T cells showed CD38-mediated downregulation of proteins but not genes of glycolytic enzymes, indicating an effect on the glycolytic machinery via posttranslational events (59) . This established CD38 as a linker between NAD + levels and the cellular glycolytic capacity; however, a more comprehensive mechanistic understanding of this observation is warranted.
In vitro, inhibiting or deleting CD38 increases intracellular NAD + levels enough to increase the activity of other NAD + -consuming enzymes such as SIRTs, leading to enhanced activity of immune cells. CD38 knockout (KO) mice were found to have elevated NAD + levels relative to wild-type controls (79) and have increased protection against tumorigenesis (80). This has led to the development of CD38 inhibitors such as daratumumab, a humanized IgG1 monoclonal antibody that targets the CD38 epitope, which is approved for the treatment of relapsed and refractory multiple myeloma (81) . Daratumumab has classic Fc-dependent immune effector mechanisms, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) and can also eliminate immune-suppressing cells, thus contributing to enhanced T-cell activity. These mechanisms were dependent on CD38 expression on the tumour and immune cells, respectively. Pre-clinical and clinical studies have demonstrated that CD38-targeting antibodies have synergistic activity with several other anti-cancer drugs.
The role of CD38 inhibitors in in vitro or in vivo infection models has not been tested yet. Despite having increased NAD + levels and probably high SIRT1 activity, CD38 KO mice were found to be more susceptible to infection by S. pneumoniae (82) and M. avium (83) because of reduced neutrophil recruitment and limited inflammatory responses. Similarly, CD38 KO mice were also susceptible to L. monocytogenes (84); however, mobilization of neutrophils from bone marrow was normal in these mice. Together this indicates a role for CD38 in the innate immune response against bacterial pathogens. Kang et al. (85) suggested a crucial role of CD38 in FcγR-mediated phagocytosis through its recruitment to the phagosome and mobilization of cADPRinduced intracellular Ca 2+ . This was associated with reduced Ca 2+ signalling and a reduced phagocytic index of CD38 −/− macrophages against Mycobacterium bovis bacillus Calmette-Guérin (BCG).
The recent past has seen the identification of small-molecule inhibitors of CD38, belonging to the flavonoid class (86) . Together this indicates that CD38 could be a possible druggable target for designing HDTs against TB and other chronic 
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infections; however, potential immunologic dysfunction could be an important side-effect of this approach.
The role of NAD + in autophagy induction-a potential mechanism to restrict infections
Mechanistic pathways associated with beneficial effects of targeting the NAD + world in aging and in neurodegenerative disorders have been well characterized (3) . Some of these mechanisms such as autophagy induction, regulated by mammalian target of rapamycin (mTOR) complex 1 (mTORC1) (87) , play an important role in maintaining intracellular homeostasis and controlling the growth of intracellular pathogens (88, 89) . The NAD + -SIRT1 axis inhibits mTOR, resulting in initiation of autophagy and autophagic flux (90) . SIRT1 also deacetylates Atg5, Atg7 and Atg8, proteins of the autophagic machinery, in a NAD + -dependent manner (90) . Additionally, SIRT1 activation induces the signalling complex containing phosphatidylinositol-3-kinase, the serine/ threonine protein kinase AKT and mTOR (PI3K-AKT-mTOR) to enhance autophagy. Contrarily, PARP1, which inhibits the NAD + -SIRT1 axis, has been shown to promote autophagy (91) . This was mediated through PARP1-catalysed Poly(ADPribosyl)ation (PARylation), leading to the dissociation of the PARP1/AMPK complex in the nucleus. The dissociated free PARylated nuclear AMPK was exported to the cytoplasm and activated autophagy. In these experiments, PARP inhibition prevented the transport of nuclear AMPK to the cytosol and decreased autophagosome formation (91) .
We have earlier shown that mice with SIRT1 knocked out specifically in macrophages were more susceptible to Mtb infection and that SIRT1-mediated autophagy induced by resveratrol was important for Mtb control (19) . Accordingly, impairment in the SIRT1 and in the autophagy network has been associated with S. Typhimurium and Mtb virulence, respectively (19, (92) (93) (94) . Additionally, by deacetylating FOXO1, SIRT1 can up-regulate the expression of Rab7 in murine cardiomyocytes, which is an important molecule regulating autophagosome-lysosome fusion (95) . Also NAM, a NAD + precursor (Fig. 1) , has been shown to induce mitophagy (selective autophagy of mitochondria) in human fibroblasts (96) . NAM also increased host fitness to restrict Staphylococcus aureus infection in mice, which was mediated by the transcription factor C/EBPε and downstream antimicrobial targets (97) .
The clinical impact of targeting the NAD + network
Approval by the US Food and Drug Administration (FDA) of PARP inhibitors, which result in increased cellular NAD + and kill cancer cells by disrupting DNA repair and replication pathways, has caused a paradigm shift in the disease management of ovarian cancer (98) . Similarly, modulation of NAD + metabolism by NAD + precursors and sirtuin activators has gained lot of momentum in last 5 years with several entering clinical trials for the treatment of type 2 diabetes, chronic obstructive pulmonary disease and cardiovascular diseases. The first clinical trial of the NAD + precursor NR involving 12 healthy subjects showed that oral NR was safe for humans, increases human blood NAD + with elevation of nicotinic acid adenine dinucleotide (NAAD) and later could be used as a biomarker of effective NAD + repletion (99) . More recently, a placebo-controlled clinical study on 120 aged (60-80-year old) healthy adults showed that repeat doses of NRPT (NR and pterostilbene, a naturally occurring analogue of resveratrol) for 8 weeks increases NAD + levels in humans safely (100) . The investigators noted a dose-dependent increase in NAD + levels that was sustained throughout the study period. These positive effects of NR on safety in humans and the well-studied role of NR on aging have led to the initiation of many efficacy studies focusing on age-related disorders (#NCT0292169, #NCT02835664, #NCT02721537 and #NCT02942888). Apart from NR, topical and oral NAM-an amide form of vitamin B 3 -has also been extensively studied in humans for skin diseases (101) .
The combination of NR and pterostilbene is hypothesized to synergistically support metabolic health because NR provides NAD + for all seven sirtuins and pterostilbene provides an additional boost to SIRT1 activity. Pterostilbene, mainly found in blueberries, has greater bioavailability and a longer half-life compared with resveratrol (102, 103) . Pterostilbene has been shown to have superior properties as an anti-bacterial agent compared with resveratrol and holds potential for treating methicillin-resistant S. aureus (MRSA) skin infections (104) , E. coli O157 (105) and Pseudomonas aeruginosa 15442 (105) . Proteomic analysis and molecular docking studies further indicated a different mechanism of action for pterostilbene in restricting MRSA from that of resveratrol (104) . In a macaque model of TB (106) , pterostilbene together with a sub-optimal drug regimen against multidrug-resistant Mtb reduced Mtb growth and pathology, compared with animals that received TB drugs alone, indicating the potential of pterostilbene as an adjunctive HDT for TB (A. Singhal and D. Kaushal, unpublished data). Additionally, both resveratrol and pterostilbene have been shown to enhance the efficacy of anti-HIV preexposure prophylaxis (PrEP) formulations (107) .
Will the beneficial effects of targeting NAD + metabolism for infectious diseases translate to humans? Topical NAM (4% gel) was safer than antibiotics against acne and did not lead to antibiotic resistance (101) . NAM also showed anti-mycobacterial capacity in two independent studies performed on TB patients in the 1940s, before the era of anti-TB drugs (108) . The use of NAM as a treatment for Mtb has, however, since faded due to the discovery of the first-line drug INH, which proved far more effective against Mtb and showed antagonism with NAM when used together as a two-drug therapeutic regimen (109) . NAM is traditionally known to exert feedback inhibition of SIRT1; therefore, it is widely used as a SIRT1 inhibitor. However, it was recently shown that, once administered to cells, NAM rapidly gets converted to NAD + , leading to increased NAD + levels and therefore an increase in SIRT1 activity. A recent meta-analysis of several studies demonstrated that NAM administration indeed stimulates SIRT1 activity and improves the functions of cells and organs (110) . The authors concluded that NAM treatment in vivo can hypothetically be stimulatory to SIRT1 (110) .
Conclusion and future perspectives
Novel therapeutic approaches and interventions are needed to treat bacterial infections so that we do not rely so heavily on antibiotics. Advanced and multi-omic studies are important in delineating whether targeting NAD + metabolism could regulate multiple defence layers in mammals like what has been demonstrated for plants, where NAD + triggers metabolic profiles similar to that of pathogen-associated molecular patterns (111) . Triggering host NAD + metabolism by abovementioned inhibitors or activators would also have an impact on the pathogen's NAD + network and their pathogenicity. Of note, biosynthesis of NAD + and NADH has been evaluated as a viable target to kill both replicating and non-replicating Mtb (112) . With the rise of drug resistance and the arrival of new structure-based chemical modulators, dissecting the role of pathogen-specific and host enzymes involved in NAD + modulation during infection becomes more relevant for future clinical applications. Overall, targeting the NAD + network has the potential to provide a powerful arsenal to fight superbugs and antibiotic resistance, thus having an enormous public health impact, especially in today's scenario when the issue of anti-microbial resistance is engulfing the world around us. 
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